Skip to main content Accesibility Help
×
×
Home

Cannabis Use as Described by People with Multiple Sclerosis

  • S.A. Page (a1), M.J. Verhoef (a2), R.A. Stebbins (a3), L.M. Metz (a4) and J.C. Levy (a5)...
Abstract:
Background:

Multiple sclerosis (MS) is one of the most common neurological diseases affecting young adults. The prevalence of MS in Alberta has been described as among the highest reported in the world, estimated at 217 per 100,000. Numerous anecdotal reports, and a few small empirical investigations have suggested that cannabis use may relieve the symptom experience of those with MS. The present study was undertaken to describe cannabis use by this patient group. Information on peoples’beliefs, practices and experiences related to use were investigated.

Methods:

Aquestionnaire was mailed to a sample of 780 adults with MS in southern Alberta, Canada.

Results:

Completed questionnaires were returned by 420/673 eligible subjects (response rate 62%). Mean sample age was 48 years and 75% were women. Respondents ranged from mildly to severely impaired. The majority of respondents (96%) was aware cannabis was potentially therapeutically useful for MS and most (72%) supported legalization for medicinal purposes. Forty-three percent had tried cannabis at some point in their lives, 16% for medicinal purposes. Symptoms reported to be ameliorated included anxiety/depression, spasticity and chronic pain. Reasons given for not trying cannabis were the fact that it is an illegal substance, concern about side effects and lack of knowledge on how to obtain it.

Conclusions:

Subjective improvements in symptom experience were reported by the majority of people with MS who currently use cannabis. Further evaluation of this substance is warranted.

RÉSUMÉ: Introduction:

La sclérose en plaques (SEP) est l’une des maladies neurologiques les plus fréquentes chez les jeunes adultes. La prévalence de la SEPen Alberta, estimée à 217 par 100 000, a été décrite comme l’une des plus élevées rapportées dans le monde. Plusieurs rapports anecdotiques et quelques études empiriques de petite taille ont suggéré que le l’utilisation de cannabis soulage les symptômes des patients atteints de SEP. Cette étude a été entreprise dans le but de décrire l’utilisation du cannabis chez ces patients. Nous avons évalué l’information sur les croyances, les pratiques et les expériences reliées à son utilisation.

Méthodes:

Un questionnaire a été posté à un échantillon de 780 adultes atteints de SEPrésidant dans le sud de l’Alberta, au Canada.

Résultats:

Quatre cent quarante des 673 sujets éligibles, soit un taux de réponse de 65%, ont retourné le questionnaire complété. L’âge moyen des participants était de 48 ans et 75% étaient des femmes. L’invalidité chez les répondants était de légère à sévère. La majorité des répondants (96%) savaient que le cannabis pouvait avoir une valeur thérapeutique dans la SEP et la plupart (72%) étaient favorables à sa légalisation à des fins médicinales. Quarante-trois pour cent avaient essayé le cannabis à un moment ou l’autre de leur vie, dont 16% à des fins médicinales. Selon les utilisateurs, les symptômes qui étaient améliorés étaient l’anxiété/la dépression, la spasticité et la douleur chronique. Les raisons fournies pour ne pas avoir essayé le cannabis étaient le fait qu’il s’agit d’une substance illégale, l’inquiétude au sujet des effets secondaires et l’ignorance sur les moyens de s’en procurer.

Conclusions:

Une amélioration subjective de la symptomatologie a été rapportée par la majorité des patients qui utilisent actuellement le cannabis. Une évaluation plus poussée de cette substance dans ce contexte est justifiée.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cannabis Use as Described by People with Multiple Sclerosis
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Cannabis Use as Described by People with Multiple Sclerosis
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Cannabis Use as Described by People with Multiple Sclerosis
      Available formats
      ×
Copyright
References
Hide All
1. Weiner, HL. A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis. Can J Neurol Sci 1998:25:93101.
2. Svenson, LW, Woodhead, SE, Platt, GH. Regional variations in the prevalence rates of multiple sclerosis in the province of Alberta, Canada. Neuroepidemiology 1994:13:813.
3. Metz, L. Multiple sclerosis: symptomatic therapies. Semin Neurol 1998:18:389395.
4. Beyerstein, B. Alternative medicine: where’s the evidence? Can J Public Health 1997:88:149150.
5. Gray, C. Legalize use of marijuana for medical purposes, MDs and patients plead. CMAJ 1998:158:373375.
6. Gruber, AJ. Marijuana and cannabinoid abuse. Pharmaceutical News 2000:7:3032.
7. Voth, EA, Schwartz, RH. Medical applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 1997:126:791798.
8. Smith, DE. Review of the American Medical Association Council on Scientific Affairs Report on medical marijuana. J Psychoactive Drugs 1998:30:127136.
9. Ashton, CH, Morgan, DR (Eds). Therapeutic uses of cannabis. Amsterdam: British Medical Association.1997.
10. Consroe, P, Musty, R, Rein, J, Tillery, W, Pertwee, R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997:38:4448.
11. Meinck, HM, Schonle, PW, Conrad, B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989:236:120122.
12. Greenberg, HS, Werness, SAS, Pugh, JE, et al. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994:55:324328.
13. Petro, DJ, Ellenberger, C. Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 1981:21: 413S–416S.
14. Clifford, DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983:13:669671.
15. Ungerleider, JT, Andyrsiak, T, Fairbanks, L, Ellison, GW, Myers, LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1988:7:3950.
16. Martyn, CN, Illis, LS, Thom, J. Nabilone in the treatment of multiple sclerosis. Lancet 1995:345:579.
17. Brenneisen, R, Egli, A, Elsohly, MA, Henn, V, Spiess, Y. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996:34:446452.
18. Killestein, J, Hoogervorst, EJL, Reif, M, et al. Safety, tolerability and efficacy of orally administered cannabinoids in multiple sclerosis. Neurology 2002:58:14041407.
19. Stenager, E, Stenager, EN, Knudsen, L, Jensen, K. The use of non-medical/alternative treatment in multiple sclerosis: a 5 year follow-up study. Acta Neurol Belg 1995:95:1822.
20. Pleines, J. Multiple sclerosis and alternative medicine. Axon 1992:13:123124.
21. Kurtzke, JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983:33:14441452.
22. Stata statistical software: release 6.0 [computer program]. College Station TX: Stata Corporation: 1999.
23. Canadian Center on Substance Abuse (CCSA). Canadian profile: alcohol, tobacco and other drugs, Ottawa. CCSA. 1999.
24. Arnold, T. Canadians favour the use of medical marijuana. National Post 138 Ed. 1999 Apr 7; 1.
25. Chang, AE, Shiling, DJ, Stillman, RC, et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: a prospective, randomized evaluation. Ann Intern Med 1979:91:819824.
26. Ohisson, A, Lindgren, AE, Whalen, A. Plasma delta-9-tetrahydro-cannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980:28:409416.
27. Zuardi, AW, Shirakawa, I, Finkelbarb, E, Karniol, IG. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology 1982:76: 245250.
28. Hall, W, Solowij, N. Adverse effects of cannabis. Lancet 1998:352:16111616.
29. Feldman, HW, Mandel, J. Providing medicinal marijuana: the importance of cannabis clubs. J Psychoactive Drugs 1998:30:179186.
30. Stebbins, RA. Tolerable differences: living with deviance. 2nd ed. Toronto:McGraw-Hill Ryerson Limited;1996.
31. Doblin, RE, Kleiman, MAR. Marijuana as anti-emetic medicine: a survey of oncologists’ experiences and attitudes. J Clin Oncol 1991:9:13141319.
32. Sibbald, B. A primer for patient’s use of medical marijuana (news). CMAJ 2001:165:329.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Canadian Journal of Neurological Sciences
  • ISSN: 0317-1671
  • EISSN: 2057-0155
  • URL: /core/journals/canadian-journal-of-neurological-sciences
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed